Two Sigma Advisers
BDSX icon

Two Sigma Advisers’s Biodesix BDSX Stock Holding History

Two Sigma Advisers’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,950
Closed -$66K – 2661
2022
Q1 		$66K Buy
1,950
+240
+14% +$15.7K ﹤0.01% 2556
2021
Q4 		$181K Buy
1,710
+760
+80% +$99.2K ﹤0.01% 2305
2021
Q3 		$156K Buy
+950
New +$180K ﹤0.01% 2287

Other funds holding BDSX

BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's BDSX Position: Q2 2022 in Review

Two Sigma Advisers sold out of Biodesix (BDSX) in Q2 2022, closing a stake of 1,950 shares — an estimated $66K sold.

Two Sigma Advisers first reported a position in BDSX in Q3 2021 and held it in 3 quarters. The position peaked at $181K in Q4 2021. 36 funds tracked by Wall St. Rank hold BDSX as of Q2 2022.

  • Two Sigma Advisers reported no remaining Biodesix position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 1,950 Biodesix shares in Q2 2022, an estimated $66K.
  • Two Sigma Advisers first reported a position in Biodesix in Q3 2021 and held it in 3 quarters.
  • Two Sigma Advisers's Biodesix position peaked at $181K in Q4 2021.
  • 36 funds tracked by Wall St. Rank held Biodesix as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.